Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1313-1322

  Paget, Christophe ^a   Duret, Helene ^a   Ngiow, Shin Foong ^a,b   Kansara, Maya ^a   Thomas, David M ^a   Smyth, Mark J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apoptosis; Hedgehog signaling pathway; Immune response; Immunogenicity; Mouse; Osteosarcoma; Proliferation

Indexed keywords

CD137 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; SONIC HEDGEHOG PROTEIN; SONIDEGIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL;

EID: 84878884888     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21680     Document Type: Article

References (33)

1. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science 2004; 304:1755-9; PMID:15205520; http://dx.doi.org/10.1126/science.1098020.
2. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010; 16:1429-33; PMID:21076395; http://dx.doi.org/10.1038/nm.2251.
3. Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011; 32:445-51; PMID:21186299; http://dx.doi.org/10.1093/carcin/bgq280.
4. Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 2012; 5:47-58; PMID:22500124; http://dx.doi.org/10.2147/OTT.S21957.
5. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009; 19:5576-81; PMID:19716296; http://dx.doi.org/10.1016/j.bmcl.2009.08.049.
6. Xu FG, Ma QY, Wang Z. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. Cancer Lett 2009; 283:119-24; PMID:19232458; http://dx.doi.org/10.1016/j.canlet.2009.01.014.
7. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-8; PMID:19726761; http://dx.doi.org/10.1056/NEJMoa0902903.
8. Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131:1735-44; PMID:21430703; http://dx.doi.org/10.1038/jid.2011.48.
9. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180-8; PMID:22670904; http://dx.doi.org/10.1056/NEJMoa1113538.
10. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-4; PMID:19726788; http://dx.doi.org/10.1126/science.1179386.
11. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486.
12. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol-031210-101324.
13. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028.
14. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269.
15. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011; 108:7142-7; PMID:21482773; http://dx.doi.org/10.1073/pnas.1016569108.
16. Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011; 6:e27306; PMID:22087285; http://dx.doi.org/10.1371/journal.pone.0027306.
17. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, et al. Role of GLI2 in the growth of human osteosarcoma. J Pathol 2011; 224:169-79; PMID:21506130; http://dx.doi.org/10.1002/path.2880.
18. Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, et al. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 2010; 9:5; PMID:20067614; http://dx.doi.org/10.1186/1476-4598-9-5.
19. Warzecha J, Göttig S, Chow KU, Brüning C, Percic D, Boehrer S, et al. Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother 2007; 19:554-61; PMID:18073155.
20. Kurita S, Mott JL, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, et al. Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells. PLoS One 2011; 6:e18330; PMID:21483830; http://dx.doi.org/10.1371/journal.pone.0018330.
21. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011; 71:5904-14; PMID:21747117; http://dx.doi.org/10.1158/0008-5472.CAN-10-4173.
22. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523.
23. Stewart GA, Lowrey JA, Wakelin SJ, Fitch PM, Lindey S, Dallman MJ, et al. Sonic hedgehog signaling modulates activation of and cytokine production by human peripheral CD4+ T cells. J Immunol 2002; 169:5451-7; PMID:12421920.
24. Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, et al. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg 2011; 254:818-23, discussion 823; PMID:22042473; http://dx.doi.org/10.1097/SLA.0b013e318236bc0f.
25. Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 2012; 72:897-907; PMID:22186138; http://dx.doi.org/10.1158/0008-5472.CAN-11-2681.
26. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96; PMID:17134371; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609.
27. Plaisant M, Giorgetti-Peraldi S, Gabrielson M, Loubat A, Dani C, Peraldi P. Inhibition of hedgehog signaling decreases proliferation and clonogenicity of human mesenchymal stem cells. PLoS One 2011; 6:e16798; PMID:21304817; http://dx.doi.org/10.1371/journal.pone.0016798.
28. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297:1559-61; PMID:12202832; http://dx.doi.org/10.1126/science.1073733.
29. Crompton T, Outram SV, Hager-Theodorides AL. Sonic hedgehog signalling in T-cell development and activation. Nat Rev Immunol 2007; 7:726-35; PMID:17690714; http://dx.doi.org/10.1038/nri2151.
30. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-?-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096.
31. Finkel MP, Jinkins PB, Biskis BO. Parameters of Radiation Dosage That Influence Production of Osteogenic Sarcomas in Mice. Natl Cancer Inst Monogr 1964; 14:243-70; PMID:14147136.
32. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 2005; 175:1586-92; PMID:16034097.
33. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199:437-48; PMID:14769851; http://dx.doi.org/10.1084/jem.20031457.